Table of Contents Author Guidelines Submit a Manuscript
Journal of Oncology
Volume 2012 (2012), Article ID 680796, 15 pages
http://dx.doi.org/10.1155/2012/680796
Review Article

Full-Length Enrich c-DNA Libraries-Clear Cell-Renal Cell Carcinoma

Institute of Biochemistry and Molecular Biology, College of Medicine, National Taiwan University, No. 1 Jen-Ai Road First Section, Taipei 100, Taiwan

Received 6 September 2011; Accepted 22 November 2011

Academic Editor: Matthew E. Hyndman

Copyright © 2012 Sai-Wen Tang and Jung-Yaw Lin. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. A. J. Pantuck, A. Zisman, and A. S. Belldegrun, “The changing natural history of renal cell carcinoma,” The Journal of Urology, vol. 166, no. 5, pp. 1611–1623, 2001. View at Google Scholar
  2. P. Russo, “Renal cell carcinoma: presentation, staging, and surgical treatment,” Seminars in Oncology, vol. 27, no. 2, pp. 160–176, 2000. View at Google Scholar · View at Scopus
  3. C. P. Pavlovich and L. S. Schmidt, “Searching for the hereditary causes of renal-cell carcinoma,” Nature Reviews Cancer, vol. 4, no. 5, pp. 381–393, 2004. View at Google Scholar · View at Scopus
  4. M. H. Bui, A. Zisman, A. J. Pantuck, K. R. Han, J. Wieder, and A. S. Belldegrun, “Prognostic factors and molecular markers for renal cell carcinoma,” Expert Review of Anticancer Therapy, vol. 1, no. 4, pp. 565–575, 2001. View at Google Scholar · View at Scopus
  5. A. Méjean, S. Oudard, and N. Thiounn, “Prognostic factors of renal cell carcinoma,” The Journal of Urology, vol. 169, no. 3, pp. 821–827, 2003. View at Publisher · View at Google Scholar · View at Scopus
  6. H. T. Cohen and F. J. McGovern, “Renal-cell carcinoma,” The New England Journal of Medicine, vol. 353, no. 23, pp. 2477–2490, 2005. View at Publisher · View at Google Scholar · View at Scopus
  7. R. J. Amato, “Chemotherapy for renal cell carcinoma,” Seminars in Oncology, vol. 27, no. 2, pp. 177–186, 2000. View at Google Scholar · View at Scopus
  8. B. R. Lane, B. I. Rini, A. C. Novick, and S. C. Campbell, “Targeted molecular therapy for renal cell carcinoma,” Urology, vol. 69, no. 1, pp. 3–10, 2007. View at Publisher · View at Google Scholar · View at Scopus
  9. D. J. van Spronsen, K. J. M. de Weijer, P. F. A. Mulders, and P. H. M. de Mulder, “Novel treatment strategies in clear-cell metastatic renal cell carcinoma,” Anti-Cancer Drugs, vol. 16, no. 7, pp. 709–717, 2005. View at Publisher · View at Google Scholar · View at Scopus
  10. T. Ishimura, I. Sakai, I. Hara, H. Eto, and H. Miyake, “Microscopic venous invasion in renal cell carcinoma as a predictor of recurrence after radical surgery,” International Journal of Urology, vol. 11, no. 5, pp. 264–268, 2004. View at Publisher · View at Google Scholar · View at Scopus
  11. P. L. Crispen, S. A. Boorjian, C. M. Lohse, B. C. Leibovich, and E. D. Kwon, “Predicting disease progression after nephrectomy for localized renal cell carcinoma: the utility of prognostic models and molecular biomarkers,” Cancer, vol. 113, no. 3, pp. 450–460, 2008. View at Publisher · View at Google Scholar · View at Scopus
  12. T. Klatte, D. B. Seligson, S. B. Riggs et al., “Hypoxia-inducible factor 1α in clear cell renal cell carcinoma,” Clinical Cancer Research, vol. 13, no. 24, pp. 7388–7393, 2007. View at Publisher · View at Google Scholar · View at Scopus
  13. E. Hirota, L. Yan, T. Tsunoda et al., “Genome-wide gene expression profiles of clear cell renal cell carcinoma: identification of molecular targets for treatment of renal cell carcinoma,” International Journal of Oncology, vol. 29, no. 4, pp. 799–827, 2006. View at Google Scholar · View at Scopus
  14. S. Amatschek, U. Koenig, H. Auer et al., “Tissue-wide expression profiling using cDNA subtraction and microarrays to identify tumor-specific genes,” Cancer Research, vol. 64, no. 3, pp. 844–856, 2004. View at Publisher · View at Google Scholar · View at Scopus
  15. M. C. Caldwell, C. Hough, S. Fürer, W. M. Linehan, P. J. Morin, and M. Gorospe, “Serial analysis of gene expression in renal carcinoma cells reveals VHL-dependent sensitivity to TNFα cytotoxicity,” Oncogene, vol. 21, no. 6, pp. 929–936, 2002. View at Publisher · View at Google Scholar · View at Scopus
  16. J. Sanjmyatav, T. Steiner, H. Wunderlich, J. Diegmann, M. Gajda, and K. Junker, “A specific gene expression signature characterizes metastatic potential in clear cell renal cell carcinoma,” The Journal of Urology, vol. 186, no. 1, pp. 289–294, 2011. View at Publisher · View at Google Scholar
  17. M. Yao, Y. Huang, K. Shioi et al., “A three-gene expression signature model to predict clinical outcome of clear cell renal carcinoma,” International Journal of Cancer, vol. 123, no. 5, pp. 1126–1132, 2008. View at Publisher · View at Google Scholar · View at Scopus
  18. M. F. Dall'Oglio, R. F. Coelho, K. R. M. Leite, J. M. Sousa-Canavez, P. S. L. Oliveira, and M. Srougi, “Gene expression profile of renal cell carcinoma clear cell type,” International Brazilian Journal of Urology, vol. 36, no. 4, pp. 410–418, 2010. View at Publisher · View at Google Scholar · View at Scopus
  19. A. R. Brannon, A. Reddy, M. Seiler et al., “Molecular stratification of clear cell renal cell carcinoma by consensus clustering reveals distinct subtypes and survival patterns,” Genes and Cancer, vol. 1, no. 2, pp. 152–163, 2010. View at Publisher · View at Google Scholar · View at Scopus
  20. M. Maruschke, D. Reuter, D. Koczan, O. W. Hakenberg, and H.-J. Thiesen, “Gene expression analysis in clear cell renal cell carcinoma using gene set enrichment analysis for biostatistical management,” British Journal of Urology International, vol. 108, no. 2, pp. E29–E35, 2011. View at Publisher · View at Google Scholar
  21. M. Takahashi, B. T. Teh, and H. O. Kanayama, “Elucidation of the molecular signatures of renal cell carcinoma by gene expression profiling,” The Journal of Medical Investigation, vol. 53, no. 1-2, pp. 9–19, 2006. View at Publisher · View at Google Scholar · View at Scopus
  22. M. E. Lenburg, L. S. Liou, N. P. Gerry, G. M. Frampton, H. T. Cohen, and M. F. Christman, “Previously unidentified changes in renal cell carcinoma gene expression identified by parametric analysis of microarray data,” BMC Cancer, vol. 3, article 31, 2003. View at Publisher · View at Google Scholar · View at Scopus
  23. Cancer Genome Atlas Research Network, “Comprehensive genomic characterization defines human glioblastoma genes and core pathways,” Nature, vol. 455, no. 7216, pp. 1061–1068, 2008. View at Google Scholar
  24. Cancer Genome Atlas Research Network, “Integrated genomic analyses of ovarian carcinoma,” Nature, vol. 474, no. 7353, pp. 609–615, 2011. View at Google Scholar
  25. J. Zhang, J. Baran, A. Cros et al., “International Cancer Genome Consortium Data Portal—a one-stop shop for cancer genomics data,” Database, vol. 2011, Article ID bar026, 2011. View at Google Scholar
  26. Y. Suzuki and S. Sugano, “Construction of a full-length enriched and a 5'-end enriched cDNA library using the oligo-capping method,” Methods in Molecular Biology, vol. 221, pp. 73–91, 2003. View at Google Scholar · View at Scopus
  27. Y. Suzuki, K. Yoshitomo-Nakagawa, K. Maruyama, A. Suyama, and S. Sugano, “Construction and characterization of a full length-enriched and a 5'-end-enriched cDNA library,” Gene, vol. 200, no. 1-2, pp. 149–156, 1997. View at Publisher · View at Google Scholar · View at Scopus
  28. S. Yamada, M. Ohira, H. Horie et al., “Expression profiling and differential screening between hepatoblastomas and the corresponding normal livers: identification of high expression of the PLK1 oncogene as a poor-prognostic indicator of hepatoblastomas,” Oncogene, vol. 23, no. 35, pp. 5901–5911, 2004. View at Publisher · View at Google Scholar · View at Scopus
  29. C. E. Nesbit, J. M. Tersak, and E. V. Prochownik, “MYC oncogenes and human neoplastic disease,” Oncogene, vol. 18, no. 19, pp. 3004–3016, 1999. View at Publisher · View at Google Scholar · View at Scopus
  30. S. W. Tang, W. H. Chang, Y. C. Su et al., “MYC pathway is activated in clear cell renal cell carcinoma and essential for proliferation of clear cell renal cell carcinoma cells,” Cancer Letters, vol. 273, no. 1, pp. 35–43, 2009. View at Publisher · View at Google Scholar · View at Scopus
  31. G. Watkins, A. Douglas-Jones, R. Bryce, R. E. Mansel, and W. G. Jiang, “Increased levels of SPARC (osteonectin) in human breast cancer tissues and its association with clinical outcomes,” Prostaglandins Leukotrienes and Essential Fatty Acids, vol. 72, no. 4, pp. 267–272, 2005. View at Publisher · View at Google Scholar · View at Scopus
  32. Q. Shi, S. Bao, L. Song et al., “Targeting SPARC expression decreases glioma cellular survival and invasion associated with reduced activities of FAK and ILK kinases,” Oncogene, vol. 26, no. 28, pp. 4084–4094, 2007. View at Publisher · View at Google Scholar · View at Scopus
  33. M. Bredel, C. Bredel, D. Juric et al., “Functional network analysis reveals extended gliomagenesis pathway maps and three novel MYC-interacting genes in human gliomas,” Cancer Research, vol. 65, no. 19, pp. 8679–8689, 2005. View at Publisher · View at Google Scholar · View at Scopus
  34. J. S. Lee, J. Heo, L. Libbrecht et al., “A novel prognostic subtype of human hepatocellular carcinoma derived from hepatic progenitor cells,” Nature Medicine, vol. 12, no. 4, pp. 410–416, 2006. View at Publisher · View at Google Scholar · View at Scopus
  35. J. H. Patel, A. P. Loboda, M. K. Showe, L. C. Showe, and S. B. McMahon, “Analysis of genomic targets reveals complex functions of MYC,” Nature Reviews Cancer, vol. 4, no. 7, pp. 562–568, 2004. View at Google Scholar · View at Scopus
  36. H. A. Drabkin, C. Bradley, I. Hart, J. Bleskan, F. P. Li, and D. Patterson, “Translocation of c-myc in the hereditary renal cell carcinoma associated with a t(3;8)(p14.2;q24.13) chromosomal translocation,” Proceedings of the National Academy of Sciences of the United States of America, vol. 82, no. 20, pp. 6980–6984, 1985. View at Google Scholar
  37. Y. Fan, Z. Liu, X. Fang et al., “Differential expression of full-length telomerase reverse transcriptase mRNA and telomerase activity between normal and malignant renal tissues,” Clinical Cancer Research, vol. 11, no. 12, pp. 4331–4337, 2005. View at Publisher · View at Google Scholar · View at Scopus
  38. L. Kozma, I. Kiss, A. Nagy, S. Szakáll, and I. Ember, “Investigation of c-myc and K-ras amplification in renal clear cell adenocarcinoma,” Cancer Letters, vol. 111, no. 1-2, pp. 127–131, 1997. View at Publisher · View at Google Scholar · View at Scopus
  39. M. Vita and M. Henriksson, “The Myc oncoprotein as a therapeutic target for human cancer,” Seminars in Cancer Biology, vol. 16, no. 4, pp. 318–330, 2006. View at Publisher · View at Google Scholar · View at Scopus
  40. J. D. Gordan, J. A. Bertout, C. J. Hu, J. A. Diehl, and M. C. Simon, “HIF-2α promotes hypoxic cell proliferation by enhancing c-myc transcriptional activity,” Cancer Cell, vol. 11, no. 4, pp. 335–347, 2007. View at Publisher · View at Google Scholar · View at Scopus
  41. H. Zhang, P. Gao, R. Fukuda et al., “HIF-1 inhibits mitochondrial biogenesis and cellular respiration in VHL-deficient renal cell carcinoma by repression of C-MYC activity,” Cancer Cell, vol. 11, no. 5, pp. 407–420, 2007. View at Publisher · View at Google Scholar · View at Scopus
  42. C. Arvanitis and D. W. Felsher, “Conditional transgenic models define how MYC initiates and maintains tumorigenesis,” Seminars in Cancer Biology, vol. 16, no. 4, pp. 313–317, 2006. View at Publisher · View at Google Scholar · View at Scopus
  43. F. de Nigris, V. Sica, J. Herrmann et al., “c-Myc oncoprotein: cell cycle-related events and new therapeutic challenges in cancer and cardiovascular diseases,” Cell Cycle, vol. 2, no. 4, pp. 325–328, 2003. View at Google Scholar · View at Scopus
  44. M. Yao, H. Tabuchi, Y. Nagashima et al., “Gene expression analysis of renal carcinoma: adipose differentiation-related protein as a potential diagnostic and prognostic biomarker for clear-cell renal carcinoma,” Journal of Pathology, vol. 205, no. 3, pp. 377–387, 2005. View at Publisher · View at Google Scholar · View at Scopus
  45. D. Sartini, G. Muzzonigro, G. Milanese, F. Pierella, V. Rossi, and M. Emanuelli, “Identification of nicotinamide N-methyltransferase as a novel tumor marker for renal clear cell carcinoma,” The Journal of Urology, vol. 176, no. 5, pp. 2248–2254, 2006. View at Publisher · View at Google Scholar · View at Scopus
  46. M. Roessler, W. Rollinger, S. Palme et al., “Identification of nicotinamide N-methyltransferase as a novel serum tumor marker for colorectal cancer,” Clinical Cancer Research, vol. 11, no. 18, pp. 6550–6557, 2005. View at Publisher · View at Google Scholar
  47. J. Xu, F. Moatamed, J. S. Caldwell et al., “Enhanced expression of nicotinamide N-methyltransferase in human papillary thyroid carcinoma cells,” The Journal of Clinical Endocrinology & Metabolism, vol. 88, no. 10, pp. 4990–4996, 2003. View at Publisher · View at Google Scholar · View at Scopus
  48. B. H. Lim, B. I. Cho, Y. N. Kim, J. W. Kim, S. T. Park, and C. W. Lee, “Overexpression of nicotinamide N-methyltransferase in gastric cancer tissues and its potential post-translational modification,” Experimental and Molecular Medicine, vol. 38, no. 5, pp. 455–465, 2006. View at Google Scholar
  49. Y. Wu, M. S. Siadaty, M. E. Berens, G. M. Hampton, and D. Theodorescu, “Overlapping gene expression profiles of cell migration and tumor invasion in human bladder cancer identify metallothionein 1E and nicotinamide N-methyltransferase as novel regulators of cell migration,” Oncogene, vol. 27, no. 52, pp. 6679–6689, 2008. View at Publisher · View at Google Scholar · View at Scopus
  50. S. W. Tang, T. C. Yang, W. C. Lin et al., “Nicotinamide N-methyltransferase induces cellular invasion through activating matrix metalloproteinase-2 expression in clear cell renal cell carcinoma cells,” Carcinogenesis, vol. 32, no. 2, pp. 138–145, 2011. View at Publisher · View at Google Scholar · View at Scopus
  51. T. J. Lee, E. M. Jung, J. T. Lee et al., “Mithramycin A sensitizes cancer cells to TRAIL-mediated apoptosis by down-regulation of XIAP gene promoter through Sp1 sites,” Molecular Cancer Therapeutics, vol. 5, no. 11, pp. 2737–2746, 2006. View at Publisher · View at Google Scholar · View at Scopus